Rheumatology

BLA Accepted for Fresenius Kabi Tocilizumab Biosimilar

August 4th 2022

By The Center for Biosimilars

In a statement, Fresenius Kabi officials said the company is rapidly expanding its portfolio in autoimmune and oncology conditions.

Vizient Market Outlook Report Predicts Trends for Adalimumab Biosimilars in 2023

August 2nd 2022

By Skylar Jeremias

Article

Vizient’s Pharmacy Market Outlook report offers predictions on how the emergence of adalimumab biosimilars in 2023 will affect the biosimilar industry and what actions should be taken in advance to ensure biosimilar adoption.

Companies Clinch Deals for Global Biosimilar Commercialization

July 26th 2022

By Skylar Jeremias

Article

Prestige Biopharma and Intas Pharmaceuticals join forces to partner on a bevacizumab biosimilar for multiple countries, and Hikma Pharmaceuticals makes a deal with Celltrion Healthcare for the commercialization of an adalimumab biosimilar.

Applications for Sandoz’ Tysabri, Humira Biosimilars Accepted for Review

July 25th 2022

By Skylar Jeremias

Article

Sandoz’ applications for its Tysabri biosimilar (natalizumab) and its high-concentration version of its Humira biosimilar (adalimumab) were accepted for review by the FDA and the European Medicines Agency.

Not So Different: How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab Market

July 24th 2022

By Skylar Jeremias

Podcast

On this podcast episode, The Center for Biosimilars spoke with Chronis Manolis from UPMC Health Plan to discuss how health care policies may shift as adalimumab biosimilars referencing Humira come to market in 2023, including how providers and payers can ensure equitable access.

Biosimilars Check-In: Celltrion Pushes for Yuflyma in Europe; Xbrane Updates on Ranibizumab Filing

July 21st 2022

By Skylar Jeremias

Article

In recent weeks, Celltrion Healthcare furthered its adalimumab biosimilar (Yuflyma) by launching the drug in Spain and Portugal and starting a clinical trial in France while Xbrane Biopharma provided an update on the FDA filing of its ranibizumab biosimilar.

Real-World Study Produces Positive Data on CT-P13 in North American Patients With IBD

July 16th 2022

By Deana Ferreri, PhD

Article

A real-world study on Pfizer and Celltrion Healthcare’s infliximab biosimilar (infliximab-dyyb, Inflectra; CT-P13) demonstrated positive clinical and patient-reported outcomes in patients with inflammatory bowel disease (IBD) in the United States and Canada.

Report: Biosimilar Uptake Accelerates in US—and So Do the Savings

July 13th 2022

By Mary Caffrey

Article

Amgen's early view said health care savings from the use of these biologic therapies climbed to $3 billion in the second quarter of 2022, for total of $18 billion over the past 6 years.

Consulting With Clinical Pharmacists May Help Boost Biosimilar Adoption

June 28th 2022

By Skylar Jeremias

Article

Having patients meet with a clinical pharmacist before a rheumatologist could help improve biosimilar adoption rates and mitigate the nocebo effect in patients with chronic diseases, according to a recent study.

After Announcing Global Biosimilar Initiative, Sandoz Sees EU Biosimilar Application Acceptance

June 20th 2022

By Skylar Jeremias

Article

Not long after the company announced its new global initiative to promote access and increase adoption of biosimilars, Sandoz’ biologics license application for its high-concentration adalimumab biosimilar was accepted by the European Union’s regulatory agency for review.